NASDAQ:EOLS Evolus (EOLS) Stock Price, News & Analysis $6.09 -0.36 (-5.58%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$6.02 -0.07 (-1.15%) As of 05/22/2026 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Evolus Stock (NASDAQ:EOLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Evolus alerts:Sign Up Key Stats Today's Range$6.08▼$6.5050-Day Range$3.94▼$6.7252-Week Range$3.86▼$10.62Volume627,516 shsAverage Volume956,208 shsMarket Capitalization$401.06 millionP/E RatioN/ADividend YieldN/APrice Target$16.00Consensus RatingModerate Buy Company Overview Evolus, Inc. is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients. The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S. Food and Drug Administration in early 2019 for the temporary improvement in the appearance of moderate to severe frown lines. Jeuveau is marketed in the United States through a direct-sales model, supported by a dedicated sales force and a digital ordering platform. Evolus has also secured rights to commercialize Jeuveau in Canada and holds distribution agreements aimed at expanding its reach into select European markets. Since launch, Evolus has invested in physician education and patient-focused support programs, collaborating with dermatologists, plastic surgeons and aesthetic specialists to build awareness of Jeuveau’s clinical profile. The company maintains a manufacturing partnership with a South Korean contract manufacturer, ensuring consistency in product quality and supply chain reliability. Evolus regularly publishes safety and efficacy data from post-marketing studies to reinforce confidence among healthcare providers and patients. Under the leadership of President and Chief Executive Officer Megan Kilcoyne, who joined Evolus in 2019 and was appointed CEO in 2020, the company has expanded its commercial infrastructure and launched new initiatives in digital engagement. Evolus continues to pursue strategic partnerships and potential development candidates that align with its mission to deliver innovative, high-quality aesthetic solutions to markets worldwide.AI Generated. May Contain Errors. Read More Evolus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreEOLS MarketRank™: Evolus scored higher than 42% of companies evaluated by MarketBeat, and ranked 636th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingEvolus has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEvolus has a consensus price target of $16.00, representing about 162.7% upside from its current price of $6.09.Amount of Analyst CoverageEvolus has only been the subject of 2 research reports in the past 90 days.Read more about Evolus' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.41) to $0.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Evolus' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.64% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 8.86.Change versus previous monthShort interest in Evolus has recently increased by 0.60%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Evolus this week, compared to 3 articles on an average week.Search Interest4 people have searched for EOLS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Evolus to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $797,184.00 in company stock.Percentage Held by Insiders5.00% of the stock of Evolus is held by insiders.Percentage Held by Institutions90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Evolus' insider trading history. Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EOLS Stock News HeadlinesEvolus, Inc. (NASDAQ:EOLS) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 21 at 3:33 AM | americanbankingnews.comEvolus to Participate in The Jefferies Global Healthcare ConferenceMay 19, 2026 | businesswire.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.May 23 at 1:00 AM | Weiss Ratings (Ad)Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in EuropeMay 11, 2026 | businesswire.comEvolus Ends ATM Facility After Strong Q1 MomentumMay 6, 2026 | theglobeandmail.comBTIG Sticks to Their Buy Rating for Evolus (EOLS)May 6, 2026 | theglobeandmail.comEvolus, Inc. (EOLS) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comEvolus Earnings Call Highlights Profitable Growth PathMay 4, 2026 | tipranks.comSee More Headlines EOLS Stock Analysis - Frequently Asked Questions How have EOLS shares performed this year? Evolus' stock was trading at $6.65 on January 1st, 2026. Since then, EOLS stock has decreased by 8.4% and is now trading at $6.09. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) posted its earnings results on Monday, May, 4th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.02. The business had revenue of $73.14 million for the quarter, compared to analysts' expectations of $72.52 million. Read the conference call transcript. When did Evolus IPO? Evolus (EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. Who are Evolus' major shareholders? Evolus' top institutional shareholders include Rice Hall James & Associates LLC (1.91%), Assenagon Asset Management S.A. (0.92%), Renaissance Technologies LLC (0.51%) and Bank of America Corp DE (0.24%). Insiders that own company stock include Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Tomoko Yamagishi-Dressler, Brady Stewart, Albert G White III, David N Gill and David N Gill. View institutional ownership trends. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/04/2026Today5/23/2026Jefferies Global Healthcare Conference 20266/04/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, EOLS's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EOLS CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees170Year Founded2014Price Target and Rating Average Price Target for Evolus$16.00 High Price Target$22.00 Low Price Target$13.00 Potential Upside/Downside+162.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.64 million Net Margins-14.39% Pretax Margin-14.10% Return on EquityN/A Return on Assets-19.03% Debt Debt-to-Equity RatioN/A Current Ratio2.04 Quick Ratio1.68 Sales & Book Value Annual Sales$301.79 million Price / Sales1.33 Cash FlowN/A Price / Cash FlowN/A Book Value($0.44) per share Price / Book-13.84Miscellaneous Outstanding Shares65,855,000Free Float62,562,000Market Cap$401.06 million OptionableOptionable Beta1.28 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:EOLS) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
